4 results
Assess whether: trimetazidine treatment 1) improves LV diastology; 2) improves LV myocardial energy content in HFpEF.
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…
Main objective: to measure the effect of trimetazidine on myocardial external efficiency in asymptomatic MYH7, MYBPC3 or TNNT2 mutation carriers Secondary objectives: to study the effect of trimetazidine on diastolic function, left ventricle and…
To evaluate whether a faecal calprotectin guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD compared with an unchanged dosing interval.